HYPERPHOSPHATEMIA IN DIALYSIS: STRATEGIES FOR MAINTAINING TARGET SERUM PHOSPHATE LEVELS

Review and Commentary from Published Literature

Robert Ting, MD, FRCP(C), FACP
Nephrologist
Scarborough Health Network (SHN)
Medical Director, Dialysis Management Clinics
Toronto, Ontario

Normand Proulx, MD, FRCP(C)
Nephrologist
CISS de L’Outaouais
Lecturer, McGill University

Guidelines for the management of advanced chronic kidney disease (CKD), including dialysis, support intensive control of elevated phosphate levels due to a broad array of complications. These include increased risk of secondary hyperparathyroidism, cardiovascular (CV) events, and death. Despite guidelines, control of hyperphosphatemia in CKD has been consistently poor. In some studies, fewer than 30% of dialysis patients have been within the target range. Phosphate binders, along with diet, are a mainstay of therapeutic strategies. Simple dosing is relevant to patient care. Due to the complexity of CKD and its many comorbidities, phosphate binders with a low pill burden are an important variable for adherence and reaching treatment targets.
Background
As declining kidney function approaches and then falls below 30 mL/min/1.73 m², the risk of hyperphosphatemia increases. One reason is that phosphate homeostasis depends on urinary excretion, a key function of the kidney. Hence, it follows that anuric patients on dialysis are at the greatest risk of hyperphosphatemia. In addition, the kidney participates in balancing parathyroid hormone (PTH), fibroblast growth factor (FGF23), vitamin D, and other biochemical factors that govern phosphorous metabolism. In defining the pathophysiology of hyperphosphatemia, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for CKD-related mineral and bone disorders emphasized the interrelationship of elevated phosphate, calcium, and PTH in CKD. Of several loops resulting in hyperphosphatemia, declining renal synthesis of vitamin D triggers a reduction in gastrointestinal (GI) absorption of calcium which may in turn stimulate a greater production of PTH resulting in a greater release of phosphorus, from bone. However, once the eGFR falls below 20-25 mL/min/1.73 m², phosphorus reabsorption is maximally suppressed, and urinary compensatory phosphate excretion may no longer keep up with phosphorus intake and release from bone, resulting in hyperphosphatemia.

Diet and phosphate binding agents are cornerstones of hyperphosphatemia treatment, but management guidelines encourage attention to the interrelationship of other associated metabolic disturbances. While phosphate binding agents are required in almost all patients with advanced kidney disease to reach guideline targets, strategies to correct other metabolic imbalances, such as vitamin D, calcium and PTH levels, are often required.

Hyperphosphatemia can be associated with muscle cramps, tetany, perioral numbness or tingling, but the degree to which these symptoms are caused by elevated serum phosphate levels or by accompanying metabolic disturbances is unclear. Patients with hyperphosphatemia can also develop bone and joint pain, pruritus and rash. For diagnosis, routine monitoring of serum phosphate, as well as serum calcium, PTH, and alkaline phosphatase, is advised once patients have Stage 3a or higher CKD, according to KDIGO guidelines. Stage 3a CKD is defined as an estimated glomerular filtration (eGFR) rate of 45–59 mL/min/1.73 m². By the time renal impairment reaches Stage 3b (eGFR 30–44 mL/min/1.73 m²) or greater severity, the guidelines recommend monitoring of serum phosphate and calcium at least every three months.

The normal serum phosphate level is variably defined. Ranges of 0.9 to 1.5 mmol/L are typical in healthy individuals, although retrospective analyses suggest risk of CKD progression is observed at levels lower than 1.5 mmol/L. In observational studies, increased concentrations of serum phosphate, which are frequently accompanied by elevations in PTH, FGF23, calcium, and calcium-phosphate product (CaxP), is associated with increased risk for valvular calcifications, left ventricular hypertrophy, heart failure, CV death, and all-cause death. Several studies with phosphate-binding therapy, including a systemic review and meta-analysis, have associated reductions in serum phosphate with improved survival.

On the basis of the large body of data associating elevated serum phosphate levels with increased mortality and the retrospective evidence associating reductions in serum phosphate with a survival benefit, the target for serum phosphate is defined in the KDIGO guidelines as the “normal range.” Prospective randomized control trials verifying and quantifying the mortality benefit from treating hyperphosphatemia have yet to be completed but are now ongoing.

CV disease, which accounts for more than 50% of deaths in patients with CKD, is regarded as the most common cause of death related to elevated serum phosphate levels. Vascular calcification, which occurs in association with the interrelated metabolic disturbances that include hyperphosphatemia, is implicated in ischemic events. Vascular calcifications are also a suspected cause of impaired CV function that leads to heart failure, sudden cardiac death, and peripheral artery disease.

There are mechanisms other than vascular calcification by which hyperphosphatemia directly or indirectly contributes to increased risk of morbidity and mortality. Due to its exacerbating effect on calcium metabolism, hyperphosphatemia either directly or indirectly increases the risk of bone pain and bone fracture related to impaired bone metabolism. It is also associated with debilitating pruritus, and it increases the risk of calciphylaxis, a rare but life-threatening complication. Secondary hyperparathyroidism, which is characterized by parathyroid gland hyperplasia, is a related but potentially independent contributor to risk of both CV and bone disease.

Management
Most patients with advanced CKD and essentially all patients on dialysis have hyperphosphatemia. Due to the risks associated with elevated serum phosphate, the KDIGO guidelines recommend active interventions to lower phosphate toward normal ranges in patients with...
Stage 3a or greater CKD severity. Although phosphorus is the essential mineral employed by cells throughout the body, phosphate, which represents a binding of oxygen to phosphorus that is used by all biological systems, is the typical target of evaluation.

There are currently 3 approaches to lowering phosphate levels in patients with CKD:

1. **Dietary restriction of phosphate intake:**
   Active intervention includes dietary restriction of foods high in phosphate that may be derived from various sources. Organic phosphate is derived from either animal protein or plant-based sources while inorganic phosphate is found in sodas and is used as an additive to prolong the shelf-life of packaged foods. Phosphate bioavailability in serum largely depends on the source, with inorganic phosphate of packaged foods and sodas having the greatest bioavailability 100%.

   Hence inorganic phosphate sources should be avoided in a patient with CKD. The bioavailability in animal protein, such as meat, fish, eggs, or milk, ranges from 40% to 60%.

   Nutritional guidelines issued by the National Kidney Foundation’s Kidney Disease Outcomes Quality initiative (KDOQI) include information on the identification of foods high in phosphates and strategies to design low-phosphate diets. Although diet can provide a meaningful reduction in serum phosphate levels, some studies indicate that less than half of patients remain adherent to diets low in phosphate.

   In patients on low phosphate diets, close monitoring of nutritional status is appropriate owing to the risk of inadequate proteins or other essential foods. Successful initiatives are likely to require education of both the patient and his or her family members, and nutritional advice tailored to the patient’s lifestyle and cultural background.

2. **Elimination of phosphate by dialysis**
   Phosphate is cleared by hemodialysis, although it is dependent on such variables as the flow rate and the characteristics of the dialyzer membrane. However, hemodialysis can only effectively remove phosphate from the serum during a typical 4 hours of dialysis treatment, which clears about 900 mg of phosphate.

   One explanation for this limited clearance is that most of the phosphate load in a CKD patient is found in the intracellular space rather than in the blood and the intra- to extracellular solute transfer rate is slow.

   Two studies have demonstrated that more phosphate can be removed with nocturnal dialysis sessions of longer duration. More typical dialysis sessions are helpful for reducing serum phosphate levels but they fall below typical dietary intake of phosphate, which occurs at a rate of 1000 mg per day even on low-phosphate diets. In more typical diets, the intake can be more than twice as high with absorption rates estimated at about 60%.25,26

3. **Reduction of intestinal absorption of phosphate:**
   Due to the limits of diet and dialysis in lowering hyperphosphatemia, phosphate binders should be considered in most or all patients with late-stage CKD and remain a standard of care in patients on dialysis and peritoneal dialysis. In the GI tract, these phosphate binders exchange an anion of phosphate found in food with a cation, such as carbonate, acetate, or citrate, to form a nonabsorbable compound excreted in the feces.

   Hence the mechanism of action of binders explains why they must be taken with meals in order to be effective. Although the licensed binders are effective, they employ several different mechanisms. Differences between agents are potentially meaningful for defining relative efficacy and safety as well as practical considerations, particularly daily pill burden.

This latter issue is relevant to the adherence essential for sustained reductions in serum phosphate. Although pill burden is just one of several obstacles for patients remaining on long-term therapy, it is a fundamental step to the goal of lowering phosphate levels to reduce associated risks. In clinical studies, non-adherence to phosphate binders has ranged widely, but there are multiple studies to suggest that only about half of patients remain adherent over prolonged periods.

**Implementing a Comprehensive Approach to Treatment**

Hyperphosphatemia and CKD typically occur in the context of multiple morbidities, including diabetes mellitus, anemia, and CV disease or risk factors for CV disease, such as hypertension, all of which require treatment. One obstacle to adherence for pharmacologic control of hyperphosphatemia is the sheer number of pharmacologic therapies required in this complex population. Due to this complexity, there is growing interest in developing multidisciplinary teams that can address the multiple health issues faced by patients with advanced CKD or who have already progressed to dialysis. There is evidence this is effective.

In a meta-analysis of 21 studies with more than 10,000 patients, multidisciplinary care models for CKD defined as teams comprised of nephrologists, cardiologists, pharmacists, and dieticians, were associated with slower rates of eGFR decline and lower rates of mortality. This type of comprehensive approach to treatment is justified. The strong correlation between number of comorbidities and survival over time supports an
aggressive approach that includes optimal adherence to therapies that slow disease progression\(^3\) (Figure 1).

**FIGURE 1 | Correlation between Number of Comorbidities and Survival Over Time**

![Figure 1](image-url)

Phosphate Binders: Selecting the Appropriate Therapy

Phosphate binders are required in most patients with advanced CKD to improve serum phosphate levels. According to the KDIGO guidelines, the target is an acceptable range, defined as 1.13 - 1.78 mmol/L, although there is no clearly-defined level above which phosphate levels impose risks. So far, there is no prospective evidence of a mortality benefit for those reaching any given target level of serum phosphate, but two randomized control trials, HiLo and PHOSPHATE\(^{31,32}\) are underway to address this question. Given the plausibility of benefit and the retrospective data supporting a reduction in mortality from treatment of elevated serum phosphate, phosphate binders remain a standard of care.

The introduction of phosphate binders into the management of advanced CKD is a relatively simple step, but these agents are not interchangeable on the basis of numerous potentially meaningful characteristics, including their mechanisms, their risk of adverse effects, their cost, and their pill burden. While aluminum hydroxide has largely fallen out of favor because of the risk of toxicity, there are three calcium-containing phosphate binders, two binders that include sevelamer, one that contains lanthanum, and sucroferric oxyhydroxide, a novel agent and the most recently approved (Table 1).

**TABLE 1 | Key Characteristics of Phosphate Binders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Daily Dose</th>
<th>Daily Pill Burden</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUCROFERRIC OXYHYDROXIDE</td>
<td>500 mg</td>
<td>2–6 chewable tablets</td>
<td>Effective; no calcium; does not lead to iron overload</td>
<td>Cost; discolored feces; modestly elevated GI side effects</td>
</tr>
<tr>
<td>Calcium acetate</td>
<td>667 mg</td>
<td>6–12 capsules</td>
<td>Effective, potentially more so than calcium carbonate with less calcium absorption</td>
<td>Potential for hypercalcemia; extra-skeletal calcification; PTH suppression; GI side effects</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>500–1250 mg</td>
<td>3–6 tablets</td>
<td>Effective, inexpensive</td>
<td>Potential for increased hypercalcemia - could lead to vascular calcification; GI side effects</td>
</tr>
<tr>
<td>Calcium citrate</td>
<td>4000–6000 mg (equivalent to 250 mg calcium per day)</td>
<td>4–6 pills</td>
<td>Effective, inexpensive</td>
<td>Enhancement of aluminum absorption; GI side effects; vascular calcification; not recommended in CKD</td>
</tr>
<tr>
<td>Sevelamer hydrochloride</td>
<td>800 mg</td>
<td>6–12 capsules</td>
<td>Effective; lipid-lowering effect; no calcium</td>
<td>Cost; GI side effects; potential development of metabolic acidosis</td>
</tr>
<tr>
<td>Sevelamer carbonate</td>
<td>800 mg</td>
<td>6–12 capsules</td>
<td>Effective; lipid-lowering effect; no calcium</td>
<td>Cost; GI side effects</td>
</tr>
<tr>
<td>Lanthanum carbonate</td>
<td>250–1000 mg</td>
<td>3–6 chewable tablets</td>
<td>Effective; no calcium</td>
<td>Cost; GI side effects; systemic absorption may be a concern due to potential for accumulation</td>
</tr>
<tr>
<td>Aluminum hydroxide</td>
<td>No safe dose identified</td>
<td>-</td>
<td>Effective, inexpensive</td>
<td>Potential for aluminum toxicity. Patient requires careful monitoring</td>
</tr>
</tbody>
</table>

Adapted from Vallée M. *International Journal of Nephrology and Renovascular Disease* 2021; 14: 301-311.
There are few controlled trials comparing these options. The calcium-based binders, calcium carbonate, calcium acetate, and calcium citrate, are widely used but not particularly good at binding phosphate and there has been concern raised by studies associating these binders with an increase in calcium load with progression of vascular calcification. The risk can be reduced by limiting the number of tablets used, but this will not permit the phosphorus targets to be achieved in most patients due to the reduced binding capacity.

The two sevelamer-containing phosphate binders, sevelamer hydrochloride and sevelamer carbonate, are also commonly used. In controlled studies, these have been associated with sustained serum phosphate reductions in patients on dialysis or peritoneal dialysis. They are not associated with risk of elevated calcium. However, sevelamer has off-target effects on the Gl tract that have included bleeding, nausea, and constipation. In some cases, such side effects as dysphagia and bowel obstruction have resulted in hospitalization and surgery. From a day-to-day patient perspective, the relative weak phosphate-binding capacity is likely to represent the biggest drawback. Both varieties of sevelamer require up to 12 pills per day to achieve treatment targets. In addition, sevelamer pills are big and must be swallowed whole, making the patient experience less enjoyable.

Lanthanum carbonate, like the sevelamer-containing drugs, does not contain calcium, but it is associated with side effects, including those involving the Gl tract as well as muscle symptoms. In typical dosing, lanthanum carbonate requires only 3 to 6 pills per day to achieve target phosphate levels, but there is a potential for substantial accumulation of this binder in the bones. The clinical consequences of this accumulation are uncertain, but this feature, along with its cost, might explain its limited use. Lanthanum tablets cannot be swallowed whole to be effective and many patients must crush the tablet before taking the binder with a meal because of their hard consistency. Furthermore, palatability is less enjoyable because of the chalky texture.

Sucroferric oxyhydroxide, the phosphate binder most recently approved, is a chewable tablet taken three times per day, with meals. When chewed, patients often report a berry-like taste, making the experience more enjoyable than the other binders. It has also demonstrated efficacy in patients with end-stage renal disease, including those on dialysis. In a phase 3 trial that conducted a direct comparison to sevelamer hydrochloride, one of the most widely-prescribed phosphate binders, sucroferric oxyhydroxide was found to be non-inferior with regard to phosphate control. However, it did have advantages, including a much lower daily pill burden (3.1 chewable pills vs. 8.1 non-chewable tablets to achieve similar phosphate levels) and a more favorable safety profile. Specifically, while Gl adverse events occurred in both study arms, they occurred at a lower rate on sucroferric oxyhydroxide (33.6% vs. 45.1%).

In another study, outcomes were compared among those maintained on sucroferric oxyhydroxide to those started on sucroferric oxyhydroxide but switched to another phosphate binder at 90 days. At 2 years, those on maintenance sucroferric oxyhydroxide were more likely to achieve a phosphate level of ≤1.78 mmol/L, had lower annual hospitalization rates, and took 50% fewer pills. In the recently published VERIFIE study, phosphorus serum levels fell from 2.03 to 1.71 mmol/L with sucroferric oxyhydroxide on an average daily dose of 2.3 pills. In addition, the proportion of patients with a serum phosphorus level <1.78 mmol/L climbed from 29.9% at study entry to 63.0% at the end of follow-up.

The most commonly reported Gl side effect reported with sucroferric oxyhydroxide is loose stools. These are mild to moderate and tended to subside early in treatment without specific therapies or treatment changes. Clinical experience has led to the suggestion of initiating sucroferric oxyhydroxide at a lower dose of 500 mg daily to be chewed with the largest meal of the day in order to minimize the risk of experiencing loose stools. Thereafter the dose may be uptitrated by 500 mg (one pill) every 2-4 weeks until the target phosphate level is achieved. The maximum daily recommended dose is 3,000 mg (6 pills) per day. Due to the iron content of sucroferric oxyhydroxide stool often becomes dark, discoloured and patients should be advised of this. Of note, studies have reported only mild systemic absorption of iron with this binder.

It has been estimated that phosphate binders represent about half of the pills required by dialysis patients. In a study evaluating the relationship between pill burden and adherence, a greater number of daily pills stratified by <3 pills, 3-6 pills, >12-15 pills, and >15 pills was associated with a stepwise increase in serum phosphorus levels. Conducted with 8,616 patients, the study also found a correlation between more pills and fewer patients in the target range for serum phosphorus (Figure 2).
There are numerous agents effective in binding phosphate for fecal excretion, but the options can be narrowed by treatment goals, including the avoidance of agents with the potential to elevate calcium and the selection of agents most likely to be compatible with sustained adherence. Relative tolerability, simplicity of dosing and potency are relative clinical advantages in general but have special relevance in patients with advancing CKD and multiple comorbidities.

Summary
The current guidelines for the management of hyperphosphatemia in advanced CKD have been derived from retrospective studies correlating elevated serum phosphate levels with increased risk of mortality. Further trials are now underway, but the available data associating lower serum phosphate levels with improved survival in CKD patients with hyperphosphatemia, particularly those on dialysis, are compelling. These data have provided the basis for current guidelines that call for serum phosphate targets within the normal range.

To achieve this target without exacerbating coexisting metabolic abnormalities, including the risk of calcium overload induced by calcium-based phosphate binders to which is linked an elevated risk of CV events, non-calcium-based phosphate binders are a cornerstone of hyperphosphatemia management. Of the multiple agents in different chemical classes available, most, but not all, impose a large pill burden, which is relevant to patient adherence. The simplest options require only three pills per day or less than half of the alternatives requiring the highest number of daily pills.

For optimal outcomes in patients with advanced CKD, a multidisciplinary team managing the multiple risks commonly shared in this population is guideline-recommended. Treatment of hyperphosphatemia cannot be isolated from other metabolic abnormalities encountered as renal function declines. ●
References


